General Objective: Estimate the seroprevalence rate of IgG and IgA anti SARS-CoV-2 antibodies over the course of 9 months of observation in people over 18 years of age, with moderate risk of exposure and associated factors, in two Andean cities of Ecuador, during the year 2022.
Specific objectives
- Estimate the cumulative incidence rate of seropositivity at 3, 6 and 9 months of observation in the entire study group and by sex, age, city and post-vaccination against COVID-19 during the year 2022.
- Estimate the median life expectancy of global seropositivity (IgG anti-SARS-CoV-2) adjusted by sex, age, city and post-vaccination against COVID-19 during the year 2022.
- To estimate the mucosal immune response rate by measuring IgA anti-SARS-CoV-2 in saliva, at 3, 6, and 9 months and post-vaccination against COVID-19.
- Estimate the susceptible fraction (anti-COVID-19 IgG – negative antibody) of the study population after 9 months of follow-up during the year 2022, considering the post-vaccination time against COVID-19.
- Determine the risk factors for exposure to SARS-CoV-2 in the study group during the year 2022, according to the indicators of the World Health Organization, WHO-ISARIC data collection form.
Participating Institutions:
UIE, ESPE, UTA.
Participants:
Director of the project Natalia Cristina Romero Sandoval.
- Ana Patricia Jimenez Arias
- Ricardo Javier Recalde Navarrete
- Jose Eduardo Leon Rojas
Awarded budget: $28231,73
Project status: In progress.
